On ASCO Day 3, AstraZeneca is dominant (again), Protagonist Therapeutics and Takeda review blood cancer data, and more.

Agent Bricks automatically optimizes AI agents on customers' unique data to deliver cost-efficient, trustworthy agents SAN FRANCISCO, June 11, 2025 /PRNewswire/ -- Data + AI Summit -- Databricks ...

How are contractors meeting the challenges of designing life sciences buildings that are fit for the future? In south London, ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

AstraZeneca targets $80bn revenue by 2030, ... AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet. Jun. 07, 2025 4:55 AM ET AstraZeneca PLC (AZN) ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...

AstraZeneca PLC closed 22.38% below its 52-week high of £133.88, which the company achieved on September 3rd.

This was the ADR's third consecutive day of losses.

AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of scheming to delay a generic version of its schizophrenia drug Seroquel ...

Paracetamol production could be revolutionized by the discovery that a common bacterium can turn everyday plastic waste into ...